Ledipasvir D-tartrate

Ledipasvir D-tartrate is an inhibitor of the hepatitis C virus NS5A , with EC 50 values of 34 pM against GT1a and 4 pM against GT1b replicon. In Vitro Ledipasvir has GT1a and 1b EC 50 values of 31 and 4 pM, respectively, and protein-adjusted EC 50 values of 210 pM (GT1a) and 27 pM (GT1b) and the intrinsic EC 50 of 39 is 310 fM for GT1a and 40 fM for GT1b. Ledipasvir is highly protein-bound both in human serum and in the cell-culture medium (containing 10% BSA) of the replicon assay. Ledipasvir exhibits an EC 50 value of 141 nM against the JFH/3a-NS5A replicon. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Ledipasvir is remarkable not only on the basis of its high replicon potency but also on the basis of its low clearance, good bioavailability, and long half-lives in rat, dog, and monkey and low predicted clearance in human. The pharmacokinetics of Ledipasvir is measured in rats and dogs. Ledipasvir shows good half-lives (rat 1.83 ± 0.22 hr, dog 2.63 ± 0.18 hr) in plasma, low systemic clearance (CL), and moderate volumes of distribution (Vss) that are greater than total body water volume . MCE has not independently confirmed the accuracy of these methods. They are for reference only. IC50& Target:EC50: 34 pM (GT1a), 4 pM (GT1b)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet